Condition: Allergic Reactions · Sponsor: ARS Pharmaceuticals, Inc.
The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.
This description comes directly from the study's public registry record.
Osnat Ehrman, MSc. · 952.334.5797 · osnate@pacificlinkconsulting.com
Always discuss trial participation with your own doctor first.
| Orso Health, Inc. | La Jolla, California, United States | Recruiting |
| Children's National Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Endeavor Health | Glenview, Illinois, United States | Recruiting |
| University Of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Weill Cornell Medicine/NewYork Presbyterian Hospital | New York, New York, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06834165